Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • How AI Frees Brokers to Focus on What Matters Most

    AI is taking on the routine work of brokerage, giving brokers more time to focus on advice, relationships, and complex client needs.

    Read more

  • On Risk Webinar Replay: AI in Insurance (Infrastructure)

    In the latest installment of William Blair’s On Risk webinar series, Adam Klauber, William Blair’s group head of the financial services and technology sector, is joined by Rich Drab, senior consultant in Capgemini’s Insurance Practice, and David Mocklow, head of insurance at Growth Protocol, for a discussion on how insurers are deploying AI across underwriting, claims, customer service, and enterprise decision-making.

    Watch the video

  • GLP-1 Users Are Moving More: What That Means for Investors

    GLP-1 users are not just eating less; they are exercising more. That shift could create new opportunities across fitness, wellness, and health-tech.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures